(ABUS) Arbutus Biopharma - Overview
Stock: RNAi Therapy, PD-L1 Inhibitor, HBV Antigens, Clinical Trials
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 48.4% |
| Relative Tail Risk | -9.11% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.40 |
| Alpha | -7.50 |
| Character TTM | |
|---|---|
| Beta | 0.898 |
| Beta Downside | 0.394 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.48% |
| CAGR/Max DD | 0.28 |
Description: ABUS Arbutus Biopharma December 25, 2025
Arbutus Biopharma Corp (NASDAQ: ABUS) is a clinical-stage biotech focused on RNA-interference (RNAi) therapeutics for infectious diseases, principally chronic hepatitis B (HBV) in the United States.
The company’s HBV pipeline includes two candidates: (1) Imdusiran, a GalNAc-conjugated, subcutaneously administered RNAi drug currently in Phase 1 and Phase 2a trials that aims to silence all HBV antigens, including HBsAg; and (2) AB-101, an oral PD-L1 inhibitor in a combined Phase 1a/1b study designed to restore HBV-specific immune responses by blocking the PD-L1 checkpoint.
Arbutus holds a licensing agreement with Alnylam Pharmaceuticals to develop and commercialize products using lipid-nanoparticle (LNP) delivery technology, leveraging Alnylam’s established manufacturing platform. The firm was originally incorporated as Tekmira Pharmaceuticals in 2005, rebranded to Arbutus in July 2015, and is headquartered in Warminster, Pennsylvania.
Key market-level data that may affect valuation: the global chronic HBV treatment market is projected to exceed $10 billion by 2028, driven by rising prevalence in Asia-Pacific and increasing demand for functional cures; RNAi therapeutics have attracted > $5 billion in venture and public funding over the past three years, indicating strong investor appetite; and as of the latest 10-Q, Arbutus reported a cash runway of roughly $45 million, sufficient for ~18 months of R&D spend under current burn-rate assumptions.
For a deeper quantitative view, you might explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -42.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.46 > 0.02 and ΔFCF/TA 4.79 > 1.0 |
| NWC/Revenue: 631.6% < 20% (prev 1689 %; Δ -1057 % < -1%) |
| CFO/TA -0.46 > 3% & CFO -45.3m > Net Income -42.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 18.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (191.8m) vs 12m ago 1.47% < -2% |
| Gross Margin: -21.81% > 18% (prev -3.94%; Δ -1786 % > 0.5%) |
| Asset Turnover: 12.27% > 50% (prev 4.80%; Δ 7.47% > 0%) |
| Interest Coverage Ratio: -415.9 > 6 (EBITDA TTM -44.6m / Interest Expense TTM 109.0k) |
Altman Z'' -15.00
| A: 0.94 (Total Current Assets 97.4m - Total Current Liabilities 5.18m) / Total Assets 97.7m |
| B: -14.09 (Retained Earnings -1.38b / Total Assets 97.7m) |
| C: -0.38 (EBIT TTM -45.3m / Avg Total Assets 119.1m) |
| D: -0.29 (Book Value of Equity -5.89m / Total Liabilities 20.3m) |
| Altman-Z'' Score: -42.59 = D |
Beneish M -3.32
| DSRI: 0.26 (Receivables 905.0k/1.61m, Revenue 14.6m/6.74m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.06 (AQ_t 0.00 / AQ_t-1 0.02) |
| SGI: 2.17 (Revenue 14.6m / 6.74m) |
| TATA: 0.03 (NI -42.3m - CFO -45.3m) / TA 97.7m) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of ABUS shares?
Over the past week, the price has changed by -7.02%, over one month by -19.83%, over three months by -13.51% and over the past year by +12.61%.
Is ABUS a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ABUS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.8 | 50.3% |
| Analysts Target Price | 5.8 | 50.3% |
| ValueRay Target Price | 4 | 4.9% |
ABUS Fundamental Data Overview February 03, 2026
P/B = 10.2624
Revenue TTM = 14.6m USD
EBIT TTM = -45.3m USD
EBITDA TTM = -44.6m USD
Long Term Debt = 922.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 531.0k USD (from shortTermDebt, last quarter)
Debt = 922.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -21.5m USD (from netDebt column, last quarter)
Enterprise Value = 701.5m USD (794.3m + Debt 922.0k - CCE 93.7m)
Interest Coverage Ratio = -415.9 (Ebit TTM -45.3m / Interest Expense TTM 109.0k)
EV/FCF = -15.47x (Enterprise Value 701.5m / FCF TTM -45.4m)
FCF Yield = -6.47% (FCF TTM -45.4m / Enterprise Value 701.5m)
FCF Margin = -310.5% (FCF TTM -45.4m / Revenue TTM 14.6m)
Net Margin = -289.4% (Net Income TTM -42.3m / Revenue TTM 14.6m)
Gross Margin = -21.81% ((Revenue TTM 14.6m - Cost of Revenue TTM 17.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.18 (Enterprise Value 701.5m / Total Assets 97.7m)
Interest Expense / Debt = 2.49% (Interest Expense 23.0k / Debt 922.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -35.8m (EBIT -45.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.80 (Total Current Assets 97.4m / Total Current Liabilities 5.18m)
Debt / Equity = 0.01 (Debt 922.0k / totalStockholderEquity, last quarter 77.4m)
Debt / EBITDA = 0.48 (negative EBITDA) (Net Debt -21.5m / EBITDA -44.6m)
Debt / FCF = 0.47 (negative FCF - burning cash) (Net Debt -21.5m / FCF TTM -45.4m)
Total Stockholder Equity = 84.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.50% (Net Income -42.3m / Total Assets 97.7m)
RoE = -50.20% (Net Income TTM -42.3m / Total Stockholder Equity 84.2m)
RoCE = -53.24% (EBIT -45.3m / Capital Employed (Equity 84.2m + L.T.Debt 922.0k))
RoIC = -42.52% (negative operating profit) (NOPAT -35.8m / Invested Capital 84.2m)
WACC = 9.21% (E(794.3m)/V(795.2m) * Re(9.22%) + D(922.0k)/V(795.2m) * Rd(2.49%) * (1-Tc(0.21)))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.70%
Fair Price DCF = unknown (Cash Flow -45.4m)
EPS Correlation: 52.07 | EPS CAGR: 25.56% | SUE: 1.30 | # QB: 1
Revenue Correlation: -64.23 | Revenue CAGR: -38.15% | SUE: -0.22 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.06 | Chg30d=+0.006 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.23 | Chg30d=+0.023 | Revisions Net=+1 | Growth EPS=+11.4% | Growth Revenue=-86.2%